JP2008524167A - ＭｙＤ８８ホモ二量体化阻害剤 - Google Patents

ＭｙＤ８８ホモ二量体化阻害剤 Download PDF

Info

Publication number
JP2008524167A
JP2008524167A JP2007546073A JP2007546073A JP2008524167A JP 2008524167 A JP2008524167 A JP 2008524167A JP 2007546073 A JP2007546073 A JP 2007546073A JP 2007546073 A JP2007546073 A JP 2007546073A JP 2008524167 A JP2008524167 A JP 2008524167A
Authority
JP
Japan
Prior art keywords
compound
pro
gly
group
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007546073A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008524167A5 (enExample
Inventor
パオロ・カルミナティ
グラツィア・ガッロ
ニコラ・ファント
ヴィトー・ルッジエロ
マリカ・サッサーノ
ドメニコ・マストロイアンニ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of JP2008524167A publication Critical patent/JP2008524167A/ja
Publication of JP2008524167A5 publication Critical patent/JP2008524167A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
JP2007546073A 2004-12-20 2005-12-16 ＭｙＤ８８ホモ二量体化阻害剤 Withdrawn JP2008524167A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04425929 2004-12-20
PCT/EP2005/056847 WO2006067091A1 (en) 2004-12-20 2005-12-16 Myd88 homodimerization inhibitors

Publications (2)

Publication Number Publication Date
JP2008524167A true JP2008524167A (ja) 2008-07-10
JP2008524167A5 JP2008524167A5 (enExample) 2009-02-12

Family

ID=34932941

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007546073A Withdrawn JP2008524167A (ja) 2004-12-20 2005-12-16 ＭｙＤ８８ホモ二量体化阻害剤

Country Status (10)

Country Link
US (1) US20080064643A1 (enExample)
EP (1) EP1828246A1 (enExample)
JP (1) JP2008524167A (enExample)
KR (1) KR20070094802A (enExample)
CN (1) CN101084240A (enExample)
AU (1) AU2005318226A1 (enExample)
BR (1) BRPI0519148A2 (enExample)
CA (1) CA2590750A1 (enExample)
MX (1) MX2007007259A (enExample)
WO (1) WO2006067091A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014527057A (ja) * 2011-08-26 2014-10-09 フォルシュングスフェアブント ベルリン エー ファウ プロリンリッチペプチドの構造模倣物およびその使用
JP2016500658A (ja) * 2012-09-26 2016-01-14 プレジデント アンド フェローズ オブ ハーバード カレッジ プロリンロックドステープルドペプチドおよびその用途
WO2017150371A1 (ja) * 2016-02-29 2017-09-08 国立大学法人大阪大学 組織損傷治療剤
US11198713B2 (en) 2017-09-07 2021-12-14 Fog Pharmaceuticals, Inc. Agents modulating beta-catenin functions and methods thereof

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0323204D0 (en) * 2003-10-03 2003-11-05 Novartis Ag Organic compounds
CN101745094A (zh) * 2010-01-28 2010-06-23 华中科技大学同济医学院附属同济医院 MyD88拓扑类肽化合物作为免疫抑制剂在医学上的用途
WO2012047175A1 (en) 2010-10-05 2012-04-12 Kemijski inštitut Fusion polypeptides comprising tir and dimerization domain for modulation of tlr/innate immunity signaling
CN102336720B (zh) 2011-03-02 2016-01-13 华中科技大学 2-氨基噻唑衍生物及制备方法和应用
ES2624981T3 (es) 2011-07-01 2017-07-18 Dana-Farber Cancer Institute, Inc. Descubrimiento de una mutación somática en el gen MYD88 en linfoma linfoplasmocitario
JP6313203B2 (ja) * 2011-07-18 2018-04-18 ユニバーシティー オブ ケンタッキー リサーチ ファウンデイションＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｋｅｎｔｕｃｋｙ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ Ａｌｕ−ｒｎａ誘導変性からの細胞の保護及び細胞保護用阻害剤
US9707235B1 (en) 2012-01-13 2017-07-18 University Of Kentucky Research Foundation Protection of cells from degeneration and treatment of geographic atrophy
WO2013112834A1 (en) * 2012-01-25 2013-08-01 Vanderbilt University Compositions and methods for treating infections
EP2847215A1 (en) * 2012-05-07 2015-03-18 Synthes GmbH Methods and devices for treating intervertebral disc disease
CA2922398C (en) 2013-09-12 2023-08-29 Dana-Farber Cancer Institute, Inc. Methods for evaluating and treating waldenstrom's macroglobulinemia
CA2930326C (en) 2013-12-06 2022-09-06 Dana-Farber Cancer Institute, Inc. Methods to distinguish waldenstrom's macroglobulinemia from igm monoclonal gammopathy of undetermined significance
USRE50030E1 (en) 2013-12-13 2024-07-02 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
WO2016092069A1 (de) 2014-12-11 2016-06-16 Forschungsverbund Berlin E.V. Inhibitoren zur hemmung der tumormetastasierung
JP2019518006A (ja) 2016-04-29 2019-06-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｙｄ８８変異型疾患における治療標的としてのｈｃｋ
CN109415413A (zh) 2016-06-07 2019-03-01 耶路撒冷希伯来大学伊森姆研究发展有限公司 髓样分化因子88(myd88)的主链环化抑制肽
ES3023183T3 (en) * 2018-01-02 2025-05-30 Univ Rush Medical Center Compositions and methods for treating neurological and other disorders
US12679842B2 (en) 2019-10-08 2026-07-14 Dana-Farber Cancer Institute, Inc. HCK as a therapeutic target in MYD88 mutated diseases
CN114746095B (zh) 2019-10-08 2025-01-24 达纳-法伯癌症研究所有限公司 Hck作为myd88突变疾病的治疗靶点
WO2024096677A1 (ko) * 2022-11-03 2024-05-10 한국과학기술연구원 Tlr 신호 억제 펩타이드 및 이를 포함하는 염증성 질환의 예방 또는 치료용 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2446458A1 (en) 2001-05-09 2002-11-14 Yale University Toll/interleukin-1 receptor adaptor protein (tirap)
US20030148986A1 (en) * 2001-12-17 2003-08-07 Cedars-Sinai Medical Center Methods for treating vascular disease by inhibiting myeloid differentiation factor 88

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014527057A (ja) * 2011-08-26 2014-10-09 フォルシュングスフェアブント ベルリン エー ファウ プロリンリッチペプチドの構造模倣物およびその使用
JP2017165761A (ja) * 2011-08-26 2017-09-21 フォルシュングスフェアブント ベルリン エー ファウＦｏｒｓｃｈｕｎｇｓｖｅｒｂｕｎｄ Ｂｅｒｌｉｎ ｅ．Ｖ． プロリンリッチペプチドの構造模倣物およびその使用
JP2016500658A (ja) * 2012-09-26 2016-01-14 プレジデント アンド フェローズ オブ ハーバード カレッジ プロリンロックドステープルドペプチドおよびその用途
JP2019142886A (ja) * 2012-09-26 2019-08-29 プレジデント アンド フェローズ オブ ハーバード カレッジ プロリンロックドステープルドペプチドおよびその用途
JP7435991B2 (ja) 2012-09-26 2024-02-21 プレジデント アンド フェローズ オブ ハーバード カレッジ プロリンロックドステープルドペプチドおよびその用途
WO2017150371A1 (ja) * 2016-02-29 2017-09-08 国立大学法人大阪大学 組織損傷治療剤
US11198713B2 (en) 2017-09-07 2021-12-14 Fog Pharmaceuticals, Inc. Agents modulating beta-catenin functions and methods thereof
US11834482B2 (en) 2017-09-07 2023-12-05 Fog Pharmaceuticals, Inc. Agents modulating beta-catenin functions and methods thereof

Also Published As

Publication number Publication date
EP1828246A1 (en) 2007-09-05
MX2007007259A (es) 2007-08-14
CA2590750A1 (en) 2006-06-29
AU2005318226A1 (en) 2006-06-29
US20080064643A1 (en) 2008-03-13
CN101084240A (zh) 2007-12-05
WO2006067091A1 (en) 2006-06-29
BRPI0519148A2 (pt) 2008-12-30
KR20070094802A (ko) 2007-09-21

Similar Documents

Publication Publication Date Title
US20080064643A1 (en) Myd88 Homodimerization Inhibitors
JP6254527B2 (ja) 構造化ポリペプチドの特異性のモジュレーション
AU2011212412B2 (en) Template-fixed peptidomimetics with CXCR7 modulating activity
US8754038B2 (en) Template-fixed peptidomimetics with CCR10 antagonistic activity
RU2668791C2 (ru) АНАЛОГИ АЛЬФА- и ГАММА-MSH
JP2016519683A (ja) 構築されたポリペプチド特異性のモジュレーション
CN102202678A (zh) Cxcr4受体化合物
AU2005229779A1 (en) Peptides and peptidomimetics binding to CD23
EP3749365A2 (en) Peptidyl inhibitors of calcineurin-nfat interaction
US5817756A (en) Pseudo- and non-peptide bradykinin receptor antagonists
JP6723195B2 (ja) プロリンリッチペプチドの構造模倣物およびその使用
US5552383A (en) Bradykinin antagonist pseudopeptide derivatives of aminoalkanoic acids and related olefins
US5811389A (en) Tri- and tetracyclic compounds
KR101238133B1 (ko) 엡티피바타이드 및 관련 중간체 화합물의 제조 방법
CN103842373A (zh) 模板-固定的肽模拟物作为fpr1的抑制物
US6245742B1 (en) Peptide antagonists of cellular mitogenesis and motogenesis and their therapeutic use
WO2012033993A2 (en) Methods for assaying enzyme activities
CN112521459B (zh) 一种stat3抑制多肽及其制备方法和应用
AU5463300A (en) Neuromedin b and somatostatin receptor agonists
Webster et al. Design and preparation of serine–threonine protein phosphatase inhibitors based upon the nodularin and microcystin toxin structures. Part 3
JP2020525484A (ja) ペプチド系化合物、その応用及びそれを含む組成物
Hariton-Gazal et al. Inhibition of nuclear import by backbone cyclic peptidomimetics derived from the HIV-1 MA NLS sequence
TW202327638A (zh) 艾帕素激導性巨環化合物及其用途
Blomberg et al. Synthesis and biological evaluation of leucine enkephalin turn mimetics
HK1113491A (en) Myd88 homodimerization inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081215

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20101108